You are here: Industry Insights > Sarepta

News List

Sarepta and Codiak BioSciences to develop rare disease therapies pharmaceutical-technology
June 24, 2020
Sarepta Therapeutics has signed a global research and option agreement with Codiak BioSciences for the design and development of engineered exosome therapeutics to treat rare, neuromuscular diseases.
Sarepta and Dyno Therapeutics Will Develop Next-Gen Gene Therapy Vectors contractpharma
May 13, 2020
Dyno’s proprietary CapsidMap platform opens up new ways to identify novel capsids.
Dyno Therapeutics launches with deals from Novartis and Sarepta pharmaceutical-technology
May 13, 2020
Biotechnology company Dyno Therapeutics has launched from stealth mode with focus on using artificial intelligence (AI) technology to develop adeno-Associated Virus (AAV) vectors.
Sarepta’s DMD therapy Vyondys 53 secures FDA accelerated approval pharmaceutical-technology
December 16, 2019
Sarepta Therapeutics has secured accelerated approval from the US Food and Drug Administration (FDA) for Vyondys 53 (golodirsen) to treat duchenne muscular dystrophy (DMD) patients with ...
Sarepta fails to receive FDA approval for DMD drug golodirsen pharmaceutical-technology
August 22, 2019
The US Food and Drug Administration (FDA) has rejected the new drug application (NDA) submitted by Sarepta Therapeutics for accelerated approval of golodirsen to treat certain Duchenne muscular dystrophy (DMD) patients.
FDA accepts Sarepta’s NDA for precision medicine Golodirsen pharmaceutical-technology
February 18, 2019
US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for its Duchenne muscular dystrophy (DMD) drug Golodirsen (SRP-4053)....
Quality blip halts Sarepta muscular dystrophy gene therapy trial fiercebiotech
July 30, 2018
A phase 1/2a trial Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) has been placed on clinical hold by the FDA after rogue DNA was found in a test sample.
Sarepta leaps 50% on early data for Duchenne gene therapy fiercebiotech
June 25, 2018
Sarepta's shares soared Tuesday morning as it presented preliminary phase 1/2 data for potentially curative gene therapy for boys with Duchenne muscular dystrophy (DMD).
Sarepta shares surge after gene therapy leads to microdystrophin expression in DMD patients pharmafile
June 22, 2018
This week, shares in Sarepta Therapeutics rocketed by 80% after the company released preliminary data from a Phase 1/2a trial showing that its experimental gene therapy
Brammer Bio, Sarepta Enter Long-term Mfg. Tie-up contractpharma
June 19, 2018
Sarepta Therapeutics, a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, has entered into a long-term strategic manufacturing partnership with Brammer B

Previous page 1 2 Next page